. 2021 Jul 8;40(3):949–982. doi: 10.1007/s10555-021-09976-0

Table 12.

Incidence of all-grade urinary adverse events in cancer patients treated with ICI [74, 76, 78, 79, 81]

Drugs/irAE	Anti-PD-1/PD-L1	Anti-CTLA-4	Combined treatment
Nephritis	0.1–0.2% [78] 0.4–2% [74] 1–2% [79]	0.2% [78] 1–2% [79]	1.0–1.3% [78] 4.5% [79] 7% [74]
Renal toxicity	0.7–0.8% [78] 2% [81]	0–2.2% [76] 0.5% [78] 2% [81]	0.3–1.5% [78] 3.5% [76] 5% [81]
Acute renal failure	0.1–0.8% [78]	0.1% [78]	1.1–1.5% [81]

Drugs/irAE

Anti-PD-1/PD-L1

Anti-CTLA-4

Combined treatment

Nephritis

0.1–0.2% [78]

0.4–2% [74]

1–2% [79]

0.2% [78]

1–2% [79]

1.0–1.3% [78]

4.5% [79]

7% [74]

Renal toxicity

0.7–0.8% [78]

2% [81]

0–2.2% [76]

0.5% [78]

2% [81]

0.3–1.5% [78]

3.5% [76]

5% [81]

Acute renal failure

0.1–0.8% [78]

0.1% [78]

1.1–1.5% [81]